BillionToOne, Inc. (BLLN)
NASDAQ: BLLN · Real-Time Price · USD
96.31
-8.84 (-8.41%)
At close: Nov 16, 2026, 4:00 PM EST
96.50
+0.19 (0.20%)
After-hours: Nov 16, 2026, 7:30 PM EST
← View all transcripts

Stifel 2026 Healthcare Conference 2026

Nov 11, 2026

Summary

Northstar's oncology differentiation rests on therapy-selection sensitivity and tissue-free response monitoring, with Q3 annualized revenue at $68 million and ~65 sales reps. Prenatal expansion is increasingly focused on health systems, with Epic-enabled volumes expected to begin in Q1-Q2 2027.

Speaker 1

Welcome back to the 2026 Stifel Healthcare Conference. We are back on the public side. Happy to have BillionToOne CEO Oguzhan Atay is with us today. Oguzhan, thanks very much for spending some time with us here.

Oguzhan Atay
CEO, BillionToOne

Thank you for inviting me.

Speaker 1

Sure. Okay, let's talk a little bit about the business. There are two sides to it. There is a prenatal business and there is an oncology business. Maybe we will start with the oncology business. You have a Northstar Select assay and you have a Northstar Response assay. Those are your two commercial products. They do exist in a crowded market. Liquid biopsy is a field we have followed for a while, and to say the least, there are a lot of players in it. But your products have differentiation that seemingly are yielding a nice ramp here on the assays themselves. The biggest question I get from investors is just how do you compete in this market, just given the nature of it? Maybe you can just spend a second talking about them, talking about why clinicians find them to be useful.

Oguzhan Atay
CEO, BillionToOne

Certainly. I think these are very crowded markets, as you said, and there are a lot of competitors that are bigger, that are spending more in these markets. But I think we have been able to show, first in prenatal, that you do not have to be spending the most to be able to be successful in a market. You do not have to be the first comer either. You just have to have much better products that you can prove to these providers that they are much better than the existing products. For different products, this can mean something different. For therapy selection, we have been able to show in peer-reviewed studies that compared to incumbents, that we have 50%+ higher sensitivity. We can detect 50%+ more actionable therapies.

That is such a high number that it is almost unbelievable, but we actually show it within these clinics as well. If they are currently using a particular product, we can offer them, "Why don't you use our test for five patients, for 10 patients, and to see for yourself that how big of an impact that it can have in their clinical journey?" And once they see it for their patients, they don't just become a user, they become an advocate. I think for Northstar Response monitoring, which this really means being able to detect progression significantly before scans in a tissue-free test. Northstar Response monitoring is an area where I think most people think of as an extension of MRD, minimal residual disease.

But in many ways, it is a distinct problem. It's a quantitative problem where you are trying to track the tumor burden. It's not a detection problem. And there, I think our technology is so much more powerful than anything that exists. That, I think, has allowed us to show that, especially as the cancer patients, in these late-stage cancer patients, their tumors evolve, the timing is so important that we can not only provide better therapies for them, and that once the cancer evolves and once the patient is no longer responding to therapy, that they can use our response to find that out. But then that also can trigger for them to do another therapy selection test to determine what the second-line therapy is going to be. So there are a lot of interplays between Northstar Select and Northstar Response tests.

Sometimes they start with doing Northstar Response tests, and then with the progression, they start ordering Northstar Select and see kind of how powerful our Northstar Select test is. Sometimes they start with head-to-head pilot research that they do against whatever test that they might be using in their clinic, see the difference, start with Northstar Select, and then they start adding Northstar Response. But we, in general, see this interplay with Northstar Select and Northstar Response in late-stage cancers. And when we get to MRD, I think that head-to-head, again, starts being very important too.

Speaker 1

Yeah.

Oguzhan Atay
CEO, BillionToOne

Right? We are trying to make a claim that they don't believe today. We are saying that you can have a tissue-free test that is as performant as tumor-informed assays.

Today, they have to make that trade-off. Do I use an easier-to-use test that is going to get me the result quickly? Or do I use a test that has a much higher failure rate, that has a much longer turnaround time, and rely on a tumor-informed test that has better sensitivity? What we are telling them is that you don't have to make this trade-off anymore. In response monitoring setting, we have already shown against the most widely used tumor-informed assay that we can actually be not just on par, but more performant than a tumor-informed assay. I think as we show that in the MRD market as well, we are going to have a significant advantage, and we are going to be able to get those providers to adopt our test.

Speaker 1

Okay. All right. There's a pretty compelling repeat usage or at least longitudinal assessment story. It sounds like it's driven in some cases by response first. I think that's interesting that you start there and then you go to the Northstar Select test. The response assay measures an epigenetic change rather than a variant, a cancer-associated variant. So in some sense, it's different than some of the response monitoring assays that are out there. Is that a distinction without a difference, so to speak? Or is that a clinically meaningful thing that you're doing versus other tests that are trying to monitor for response and resistance?

Oguzhan Atay
CEO, BillionToOne

I think it can be meaningful, especially if the tumor evolves and you are looking at only particular variants, you might be able to miss that evolution. Whereas when you are looking at an epigenetic change, you can look at much more broadly, because those epigenetic changes happen across the epigenome, whereas the variant changes can be happening in genes that you might not even be assessing.

Speaker 1

Okay. The confidence that clinicians will appreciate the performance difference is presumably high, because one of the things that we run into, and we realize more and more every day, is that the folks that are thinking about sensitivity of cancer assays, most are guys like me and investors, far more than clinicians. But it sounds like your point is, when these clinicians sort of get into the weeds a little bit and realize what they can do for their patients, that the sensitivity advantage or the performance advantage is what ends up winning the day.

Oguzhan Atay
CEO, BillionToOne

I think it really depends on how big of a difference that you have. Like a 5% difference is going to be very difficult to convince a physician for. That is why in therapy selection, we are focusing on the sensitivity difference, because we can say that 50% more actionable variants is so significant that you can see the difference in just a few patients. That is not going to be the case when you go into an MRD use case. That is why we are focused there on tissue-free tests, because you need to have almost a categorical difference, that it is much easier to use it as a tissue-free test with the performance of a tumor-informed test, as opposed to kind of saying that we have a more performant tumor-informed test.

I think the latter is going to be a little bit more difficult to convince physicians, especially in some of the more highly shedding cancer types. I think that starts becoming more meaningful in some of the other cancer types as MRD utilization goes from primarily CRC today to lower and lower shedding cancer types. But today, in CRC, I think that differentiation, as you said, might not be as clinically meaningful. That is why the more meaningful differentiation is that all-important ease of use.

Speaker 1

Yeah. Okay. Is it fair to say that as we move out of some of these high-shedding cancers, or cancers where liquid biopsy assays have just been deployed and kind of well-established, that your sensitivity advantage kind of drives home a message for these clinicians that resonates in a way that maybe some of these other ones aren't? In other words, do you think you out-kick your coverage, so to speak, in some of these lower-shedding, less penetrated oncology markets from a tumor standpoint?

Oguzhan Atay
CEO, BillionToOne

I mean, especially we see that in therapy selection today, right? If you look at in therapy selection, as you go to lower and lower shedding cancer types, our differentiation, our advantage becomes larger.

Speaker 1

Okay. Okay. That's performance. Can we maybe just talk a little bit about commercial reach? I was asking you about regional penetrations and just how the sales force is reaching doctors. I think you started the year with a mid 50s number as far as the number of reps that you have, and you're trying to get to 65 at the year end, provided that that target still holds. Are you on track for that? The related question can just be like, how much do you see that expansion being meaningful in the market, knowing that some of these reps are still in the process of coming up now?

Oguzhan Atay
CEO, BillionToOne

We have about 65 sales representatives in oncology right now. We are certainly on track and potentially beyond that year-end target already. We are seeing incredible sales efficiency. As you know, in our Q3 results, we are already at $68 million annualized revenues. That means that each sales rep on average is bringing in more than $1 million. That is without Northstar Response Medicare coverage. That is actually, as you said, with a significant number of these reps are just ramping up.

Speaker 1

Still getting trained.

Oguzhan Atay
CEO, BillionToOne

Not really contributing as much. We actually see a very strong sales efficiency in oncology, and that is why our growth is actually not really determined by how many sales reps that we can add or we should add. It is that there is a natural rate beyond which it is very difficult to maintain the same level of service and quality. We look at kind of, okay, if you want to maintain 100% year-over-year growth in oncology, but not very significantly above that, from a test volume perspective, how many reps do we need to add every quarter to be able to grow at that level, but not much more beyond that level? Because growing much beyond that level can result in service quality to be not as good. You can have the greatest test, greatest product in the world.

If your turnaround time is three weeks, oncologists are going to not rely on your test.

Speaker 1

I see. Okay, so there's a sweet spot in terms of the number of sales reps that you want out there. It sounds like that's somewhere in between 60 to 100, or 100 as the upper limit?

Oguzhan Atay
CEO, BillionToOne

No, I think

Speaker 1

In the near term?

Oguzhan Atay
CEO, BillionToOne

I think it is about how many you add every quarter to maintain that growth rate that you can sustain. As the base grows, the number of reps that you want to add per quarter needs to grow to be able to maintain that.

Speaker 1

Okay

Oguzhan Atay
CEO, BillionToOne

maintain that 100% rate. That was about five to six representatives for 2026. That can be seven to eight sales representatives per quarter next year so that we can continue to maintain that 100% year-over-year growth for years to come.

Speaker 1

Okay. Okay. Maybe just thinking a little bit about in-network versus out-of-network status for tests. When it comes to ordering logistics, and just the way in which these docs tend to prefer some tests over others, some are in-network, some are not. Where are you, generally speaking, when it comes to growing your in-network percentage of tests, and what kind of progress do you think you make on that in 2027?

Oguzhan Atay
CEO, BillionToOne

We are about 90% in-network, and this becomes actually a much more important point, especially in prenatal side. I think in oncology, most of the reimbursement and coverage is driven by Medicare and Medicare Advantage plans. But in prenatal, there are a lot of managed Medicaid programs and other difficulties when you are out of network that can result in a significant headwind from a test volume growth perspective as well as ASP perspective. That is why it was so important for our prenatal to get in-network. We talked previously about how 40% of the prenatal market is in single specialty clinics, where we have done a lot of penetration in, and 60% is in health systems.

Until this year, we couldn't even get into many of these health system conversations, because if you are not in-network with the major insurance players in the country, you don't even have a chance to become their primary test. We have the 60% of prenatal market in health systems that we really couldn't start penetrating until this year because we weren't in-network with all major insurance players, because we weren't investing in Epic Aura, and because we didn't have the full product portfolio, including the expanded panels. Now that we have all the building blocks for health system penetration in prenatal, I think over long term, the 60% of the market is going to be an incredible opportunity for us to continue to grow our market share.

Speaker 1

Okay. That makes total sense. Penetrating the health system base obviously is an objective of yours for 2027. It takes some time for those institutions to kind of get their hands around it and get on board. Do you see progressive wins over the course of 2027, or is it more by the end of the year we think we'll start putting some numbers on the board, and that kind of sets you up for a 2028 volume uplift?

Oguzhan Atay
CEO, BillionToOne

I think it is difficult to say when exactly they are going to come in. We had about, I think, three wins in 2025, and then we had about one health system win in 2026, and those are the two data points. Now, of course, we have a lot more building blocks in place. I think it can be one, it can be three, it can be five of them, but each one being 3,000, 4,000 tests per quarter, they can be substantial additive growth that are not in our models, that are not going to be in the way that we guide for next year.

Speaker 1

Yeah.

Oguzhan Atay
CEO, BillionToOne

Our baseline kind of growth in the independent single specialty clinics is where we are going to continue to see predictable quarter-over-quarter growth in our prenatal business. Continued growth in our ASPs will contribute to that year-over-year growth for our prenatal business. Health systems are actually going to be, I think, an upside potential, and the magnitude of that, I think, still is going to be a question mark, because each one is so significant that there is a big difference if we get one of them versus four of them.

Speaker 1

Yeah, for sure. Okay. You mentioned the 130 gene panel, or at least the expanded panel. It sounds like that's an important part of what you're trying to do. Is that from a clinical standpoint, the health systems feel more comfortable using it, or I would imagine the genetic counselors also have something to say about that. Why is that product important there? If you could just spend a minute there.

Oguzhan Atay
CEO, BillionToOne

Yeah. I think if you think about health systems, you have to have products that speak to every single stakeholder. We had the ease of use of our workflow and the best-in-class single-gene NIPT that OBGYNs love. We had the Fetal Antigen NIPT that is so critical to maternal-fetal medicine specialists. I mean, they see more alloimmunized patients than high-risk Down syndrome aneuploidy patients. So, we had those two stakeholders that have been pushing for our adoption in health systems. Not only we didn't have an expanded single-gene NIPT, we didn't even have the traditional carrier panels that are expanded until this year. What that meant was, in these health systems, genetic counselors who take care of the rare conditions and counseling for these conditions due to family history, or they tend to like these larger panels.

Even though most of the testing, maybe 95% of the testing, are driven by OBGYNs and MFMs, we weren't serving fully the needs of genetic counselors that really need these expanded panels. So by offering this, it is not that we expect suddenly vast majority of our volume to come in from 130 gene, but now we become a true contender for health systems because now we are serving the needs of genetic counselors as well.

Speaker 1

Yeah. You're in the game there. Okay. Okay. You also mentioned EMR. You had the announcement at the beginning of the year that you're now in the process, or you're at this point maybe integrated with the Epic Aura system. I know that that takes time as well, but if you talk to other players in the market, they do tend to see a benefit, I would say, somewhat fairly quickly in terms of volumes from just having that process be more ironed out. Is that something you're seeing, and then what do you think that portends for the future as they work through that?

Oguzhan Atay
CEO, BillionToOne

Yeah, we have integrated with Epic Aura faster than any lab. They have a scorecard, and we did it faster than any lab. I think it speaks to our execution ability. But of course, even after you integrate with Epic Aura, you need to go integrate with each health system. And we have first done that with a few health systems that we have been able to get onboarded in 2025 and 2026 that were already using us, because what you see is that, as you mentioned, even for people, the systems that are using you or clinics that are using you, being EMR integrated results in both those places to be stickier, but also an uplift in the test volume that they are sending. And we certainly see that.

Speaker 1

You do? Okay.

Oguzhan Atay
CEO, BillionToOne

We do. We have already started seeing some benefits of those existing places. But the primary reason that we wanted to invest in Epic Aura is new health systems. And that is something that we are still working through, because it's not just about integrating with Epic with these health systems. They have a number of kind of phases that they have to go through, from cybersecurity review to Epic Aura integration to phlebotomy agreement to vendor approval. So, even if you have their clinical committee already made the decision that we are going to use BillionToOne for all of our testing, it can still take six, nine, 12, sometimes even more months before you actually get the full kind of switch. And it is a switch-like transition when it happens.

Speaker 1

Okay. So, if that was January, or at least that was when the announcement was, and it could take 6- 12 months, then arguably now-ish is when you think you're really going to start to see the volumes meaningfully, I don't want to say inflect, but you should see the result of that being turned on. Is that fair?

Oguzhan Atay
CEO, BillionToOne

Yeah, I think Epic Aura, we integrated by Q2, so I think we should start seeing it probably in Q1, Q2.

Speaker 1

Beginning of 2027.

Oguzhan Atay
CEO, BillionToOne

Beginning of 2027.

Speaker 1

Do prenatal and oncology get turned on at the same time, so to speak?

Oguzhan Atay
CEO, BillionToOne

For the vast majority of the health systems, yes.

Speaker 1

Okay. Got to talk about competition a little bit. When we were working with you guys on the IPO, it was very clear that the idea that you do not need the father's sample was an advantage. That resonated in pretty much every doc conversation that we had. Natera is the incumbent in the space. They launched a Fetal Focus assay, and our survey work suggested that some of these docs might be at least interested in what they have there. It does not look like the performance of those two tests is on par with one another, but it does seem like it is a change in the competitive environment. I would love it if you could just spend a second talking about whether you think that assay for that company makes a difference for your prenatal volumes.

Oguzhan Atay
CEO, BillionToOne

I think it does change the conversation in the sense that you now have to explain how you are differentiated against that competition. You need to go through your data, your clinical studies. But it is a field that we have really created as a category, and we have so many more clinical studies and evidence around this. The other thing is that the competition's assay is primarily designed to rely on still partner testing, right? The test works better when the partner testing is done, because it relies on the linked SNPs. From that perspective, even the workflow and the positioning are actually different. Ours is as performant when the partner testing is not done, whereas I think the alternative positioning is that, let us try to do partner testing, and if the partner testing cannot be completed, this can be used.

That differentiation already makes a big difference, I think, in OB/GYN clinics. But I would also say that I am very hands-on. I conduct almost daily sales calls. When you have daily sales calls, like in the past two months, I might have had 40 of these. I do not think I heard the name of that competing product once, because these sales calls, what happens is that you are really trying to solve problems around phlebotomy, logistics, the agreement that they need to sign for vendor approval. All of these steps actually are much more important, because even if you go and repeat that survey or those discussions, and you talk to even providers that are not using us, right?

As long as I think an unbiased party explains what these products are, I think we'll get nine out of 10 physicians to still say that we have a great amount of differentiation from Fetal Antigen NIPT to how our RHD NIPT actually works across all U.S. populations. The competition's test does not. How our single-gene NIPT has so much evidence and works as well when the partner testing is not done. We can prove that we have the better products, but that is not- that doesn't determine that you actually get them to use you. Unless you are easy to use, you are in the EMR, you are still fighting that battle. A lot of the times, our battle is not against the competition, it is actually against inertia.

When we do this analysis every month of the top 10 accounts that we receive, from which competition, and we have been doing this for more than two years, it literally did not change in these two years, that the number of accounts that we receive from each of the competitor stay the same throughout this period. That really, I think, speaks to how it is not really about as much product differentiation, but it is about being able to move against the inertia of a large health system and how long it takes for them to switch.

Speaker 1

Okay. So you assess new business wins versus switches from competitors. Switches from competitors data does not look like it's changing, gives you confidence that the competitive dynamic is not different than what it was, at least as far as volumes go. On the new business wins, what is changing? I mean, what are you noticing between an independent clinic that comes on at the end of 2026 versus one that was last year? Is it simply awareness?

Oguzhan Atay
CEO, BillionToOne

I think it is. If you look at independent clinic market of being 40%, it is so much easier to grow like 50%, 100% year-over-year when you are growing from 10% market share to 20% market share. You can't grow another 100% from 20% market share to 40% market share. Part of the dynamics is that we are at a different part of the S-curve in the independent clinic wins, and that is why health system has become a much bigger part of our growth strategy in the long term.

Speaker 1

Okay. Is your rep activity going to be will incentives or just the focus for the reps evolve to come to be more focused on the health systems, and is that something that you think just the evolution of that? Obviously, the number of reps will be greater, but also the focus seems like it's an important element for 2027 as well.

Oguzhan Atay
CEO, BillionToOne

Certainly.

Speaker 1

Correct me if I'm wrong on that.

Oguzhan Atay
CEO, BillionToOne

Yeah. I think in independent clinics, the more reps that you add, the more wins that you are going to have. But with health systems, you are not going to change how fast the health system moves by adding more reps into that particular region that health system operates in. Also, historically, we have incentivized our sales team to focus on quarterly goals, right? Quarter-over-quarter growth every single quarter, right? They have to hit that number. That focused them so much on the single specialty clinics as well, because they are not going to get a health system to switch over the course of three months. So we are, of course, making certain changes to balance that quarterly growth with the health system focus and with annual sales cycles that health systems have.

Speaker 1

Yeah. Okay. I need to go back to oncology for one quick question, then I'm going to ask you a margin question as well. On the oncology side, what do you think remains unsolved from MolDX on response? We're getting down to it. I mean, it's almost December. It feels like maybe the decision there on their part is more of a 2027 thing. But what is it that you think that they're still working on?

Oguzhan Atay
CEO, BillionToOne

What we realized was that we were being asked for cancer type by cancer type level evidence that no tumor-informed assay was asked for, and the increasingly rarer cancer types. That really, I think, told us that the concern from MolDX is not really about the cancer type data, but it is about whether a tissue-free test can perform as well as a tumor-informed test. They haven't given longitudinal immunotherapy coverage to really any tissue-free test in the past, whereas I think tumor-informed tests, even without showing cancer type by cancer type evidence, have been able to get those coverage decisions.

For us, doing the head-to-head against a widely used tumor-informed assay that has coverage was a way to convince MolDX that this is as performant, and that comparison was done pan-cancer, and that is why we believe that this can be the evidence that moves MolDX towards coverage.

Speaker 1

Yeah. Okay, very helpful. Last one on margins. You are ahead of the game there when it comes to comparison to peers. I have a double-digit EBITDA margin in my model for 2026. Guardant and Natera still burning through money, losing money. Where does a 10% EBITDA margin go over the next couple of years when you think about just investment and then some of the things you need to do, but also goals that you'd like to have on profitability?

Oguzhan Atay
CEO, BillionToOne

Yeah. I think every product line that we build, every investment decision that we make is done so that each of these product lines can reach 70%-80% gross margins, if not higher, and that the operating margin on a product line basis can be 30% plus. But that doesn't mean that we are going to reach 30% GAAP operating margin next year or the following year, because we continue to invest in new areas. These are such large markets that earlier parts of our business, with 30+% operating margins, are used to grow into larger and larger markets that take more and more investments. For us, the GAAP profitability is a must-have, but as we get into larger and larger markets, I think we are not going to see significantly increased profitability on a company-wide basis.

But on an individual product basis, we are going to see more and more products joining the 30%+ operating margins. And I think over long term, as all of our product portfolio matures, that is where we want to be.

Speaker 1

Okay. We are at time. Oguzhan, thank you very much for coming to the conference. Appreciate it.

Oguzhan Atay
CEO, BillionToOne

Thank you.